Ambalal Sarabhai Enterprises Share Price
Sector: Major Drugs
You have to be logged in to add this to Watchlist.
Login or Register
37.51 -0.44 (-1.16%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
37.30
Today’s High
38.07
52 Week Low
34.11
52 Week High
77.70
Key Metrics
- Market Cap (In Cr) 287.45
- Beta 1.14
- Div. Yield (%) 0
- P/B 2.12
- TTM P/E 30.46
- Peg Ratio -0.51
- Sector P/E 26.62
- Open Price 37.95
- Prev Close 37.95
Ambalal Sarabhai Enterprises Analysis
Price Analysis
-
1 Week-3.09%
-
3 Months-22.96%
-
6 Month-26.34%
-
YTD-29.17%
-
1 Year-20.97%
Risk Meter
- 53% Low risk
- 53% Moderate risk
- 53% Balanced Risk
- 53% High risk
- 53% Extreme risk
Ambalal Sarabhai Enterprises Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 173.57
- Selling/ General/ Admin Expenses Total
- 63.02
- Depreciation/ Amortization
- 3.57
- Other Operating Expenses Total
- -0.59
- Total Operating Expense
- 168.28
- Operating Income
- 5.29
- Net Income Before Taxes
- 6.65
- Net Income
- 5.68
- Diluted Normalized EPS
- 0.74
- Period
- 2024
- Total Assets
- 250.23
- Total Liabilities
- 113.1
- Total Equity
- 137.13
- Tangible Book Valueper Share Common Eq
- 14.69
- Period
- 2024
- Cashfrom Operating Activities
- 4.72
- Cashfrom Investing Activities
- -1.13
- Cashfrom Financing Activities
- -2.95
- Net Changein Cash
- 0.65
- Period
- 2023
- Total Revenue
- 170.28
- Selling/ General/ Admin Expenses Total
- 56.12
- Depreciation/ Amortization
- 2.76
- Other Operating Expenses Total
- -1.31
- Total Operating Expense
- 161.49
- Operating Income
- 8.79
- Net Income Before Taxes
- 15.17
- Net Income
- 11.45
- Diluted Normalized EPS
- 1.49
- Period
- 2023
- Total Assets
- 245.74
- Total Liabilities
- 114.82
- Total Equity
- 130.92
- Tangible Book Valueper Share Common Eq
- 13.88
- Period
- 2023
- Cashfrom Operating Activities
- 5.72
- Cashfrom Investing Activities
- -16.78
- Cashfrom Financing Activities
- 9.09
- Net Changein Cash
- -1.97
- Period
- 2022
- Total Revenue
- 196.75
- Selling/ General/ Admin Expenses Total
- 54.33
- Depreciation/ Amortization
- 2.32
- Other Operating Expenses Total
- -1.13
- Total Operating Expense
- 186.34
- Operating Income
- 10.41
- Net Income Before Taxes
- 54.19
- Net Income
- 47.22
- Diluted Normalized EPS
- 4.53
- Period
- 2022
- Total Assets
- 230.5
- Total Liabilities
- 110.63
- Total Equity
- 119.87
- Tangible Book Valueper Share Common Eq
- 12.44
- Period
- 2022
- Cashfrom Operating Activities
- 11.47
- Cashfrom Investing Activities
- 5.08
- Cashfrom Financing Activities
- -19.19
- Net Changein Cash
- -2.64
- Period
- 2021
- Total Revenue
- 163.64
- Selling/ General/ Admin Expenses Total
- 62.8
- Depreciation/ Amortization
- 2.41
- Other Operating Expenses Total
- -0.87
- Total Operating Expense
- 165.09
- Operating Income
- -1.45
- Net Income Before Taxes
- 32.54
- Net Income
- 29.36
- Diluted Normalized EPS
- 1.53
- Period
- 2021
- Total Assets
- 210.05
- Total Liabilities
- 136.15
- Total Equity
- 73.9
- Tangible Book Valueper Share Common Eq
- 6.44
- Period
- 2021
- Cashfrom Operating Activities
- -2.3
- Cashfrom Investing Activities
- 10.09
- Cashfrom Financing Activities
- -5.84
- Net Changein Cash
- 1.95
- Period
- 2020
- Total Revenue
- 133.5
- Selling/ General/ Admin Expenses Total
- 54.1
- Depreciation/ Amortization
- 2.57
- Other Operating Expenses Total
- 0.3
- Total Operating Expense
- 136.86
- Operating Income
- -3.36
- Net Income Before Taxes
- 14.94
- Net Income
- 14.06
- Diluted Normalized EPS
- 1.8
- Period
- 2020
- Total Assets
- 186.45
- Total Liabilities
- 141.68
- Total Equity
- 44.77
- Tangible Book Valueper Share Common Eq
- 2.63
- Period
- 2020
- Cashfrom Operating Activities
- -6.88
- Cashfrom Investing Activities
- 16.89
- Cashfrom Financing Activities
- -14.22
- Net Changein Cash
- -4.21
- Period
- 2019
- Total Revenue
- 151.88
- Selling/ General/ Admin Expenses Total
- 53.28
- Depreciation/ Amortization
- 2.1
- Other Operating Expenses Total
- 1.7
- Total Operating Expense
- 147.11
- Operating Income
- 4.77
- Net Income Before Taxes
- 8.21
- Net Income
- 4.25
- Diluted Normalized EPS
- 0.55
- Period
- 2019
- Total Assets
- 217.3
- Total Liabilities
- 186.68
- Total Equity
- 30.62
- Tangible Book Valueper Share Common Eq
- 0.78
- Period
- 2019
- Cashfrom Operating Activities
- 18.8
- Cashfrom Investing Activities
- -9.25
- Cashfrom Financing Activities
- -6.07
- Net Changein Cash
- 3.49
- Period
- 2018
- Total Revenue
- 125.62
- Selling/ General/ Admin Expenses Total
- 28.05
- Depreciation/ Amortization
- 2.12
- Other Operating Expenses Total
- 39.15
- Total Operating Expense
- 139.52
- Operating Income
- -13.9
- Net Income Before Taxes
- 7.96
- Net Income
- 1.28
- Diluted Normalized EPS
- -1.06
- Period
- 2018
- Total Assets
- 200.25
- Total Liabilities
- 173.74
- Total Equity
- 26.52
- Tangible Book Valueper Share Common Eq
- 0.24
- Period
- 2018
- Cashfrom Operating Activities
- -7.39
- Cashfrom Investing Activities
- 17.58
- Cashfrom Financing Activities
- -2.09
- Net Changein Cash
- 8.1
- Period
- 2024-12-31
- Total Revenue
- 45.97
- Selling/ General/ Admin Expenses Total
- 7.63
- Depreciation/ Amortization
- 0.99
- Other Operating Expenses Total
- 11.48
- Total Operating Expense
- 47.66
- Operating Income
- -1.69
- Net Income Before Taxes
- 2.93
- Net Income
- 2.23
- Diluted Normalized EPS
- 0.29
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 44.7
- Selling/ General/ Admin Expenses Total
- 7.72
- Depreciation/ Amortization
- 1.01
- Other Operating Expenses Total
- 10.64
- Total Operating Expense
- 43.18
- Operating Income
- 1.52
- Net Income Before Taxes
- 3.11
- Net Income
- 2.62
- Diluted Normalized EPS
- 0.34
- Period
- 2024-09-30
- Total Assets
- 260.46
- Total Liabilities
- 120.07
- Total Equity
- 140.39
- Tangible Book Valueper Share Common Eq
- 15.12
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -7.05
- Cashfrom Investing Activities
- -1.93
- Cashfrom Financing Activities
- 1.59
- Net Changein Cash
- -7.39
- Period
- 2024-06-30
- Total Revenue
- 40.7
- Selling/ General/ Admin Expenses Total
- 7.21
- Depreciation/ Amortization
- 0.98
- Other Operating Expenses Total
- 9.43
- Total Operating Expense
- 40.84
- Operating Income
- -0.14
- Net Income Before Taxes
- 0.84
- Net Income
- 0.35
- Diluted Normalized EPS
- 0.05
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 54.35
- Selling/ General/ Admin Expenses Total
- 7.14
- Depreciation/ Amortization
- 0.25
- Other Operating Expenses Total
- 10.66
- Total Operating Expense
- 48.87
- Operating Income
- 5.48
- Net Income Before Taxes
- 7.56
- Net Income
- 8.29
- Diluted Normalized EPS
- 1.08
- Period
- 2024-03-31
- Total Assets
- 250.23
- Total Liabilities
- 113.1
- Total Equity
- 137.13
- Tangible Book Valueper Share Common Eq
- 14.69
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4.72
- Cashfrom Investing Activities
- -1.13
- Cashfrom Financing Activities
- -2.95
- Net Changein Cash
- 0.65
- Period
- 2023-12-31
- Total Revenue
- 43.11
- Selling/ General/ Admin Expenses Total
- 7.29
- Depreciation/ Amortization
- 1.13
- Other Operating Expenses Total
- 9.44
- Total Operating Expense
- 41.72
- Operating Income
- 1.4
- Net Income Before Taxes
- 1.88
- Net Income
- 1.18
- Diluted Normalized EPS
- 0.15
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 40.01
- Selling/ General/ Admin Expenses Total
- 6.9
- Depreciation/ Amortization
- 1.14
- Other Operating Expenses Total
- 8.61
- Total Operating Expense
- 40.09
- Operating Income
- -0.08
- Net Income Before Taxes
- 1.81
- Net Income
- 1.08
- Diluted Normalized EPS
- 0.15
- Period
- 2023-09-30
- Total Assets
- 240.24
- Total Liabilities
- 113.2
- Total Equity
- 127.04
- Tangible Book Valueper Share Common Eq
- 13.35
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -3.51
- Cashfrom Investing Activities
- -1.84
- Cashfrom Financing Activities
- 0.11
- Net Changein Cash
- -5.25
- Period
- 2023-06-30
- Total Revenue
- 36.1
- Selling/ General/ Admin Expenses Total
- 6.37
- Depreciation/ Amortization
- 1.05
- Other Operating Expenses Total
- 9.83
- Total Operating Expense
- 40.15
- Operating Income
- -4.04
- Net Income Before Taxes
- -4.6
- Net Income
- -4.87
- Diluted Normalized EPS
- -0.64
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 44.44
- Selling/ General/ Admin Expenses Total
- 7.53
- Depreciation/ Amortization
- 0.92
- Other Operating Expenses Total
- 8.34
- Total Operating Expense
- 42.01
- Operating Income
- 2.43
- Net Income Before Taxes
- 6.93
- Net Income
- 5.49
- Diluted Normalized EPS
- 0.69
- Period
- 2023-03-31
- Total Assets
- 245.74
- Total Liabilities
- 114.82
- Total Equity
- 130.92
- Tangible Book Valueper Share Common Eq
- 13.88
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 5.72
- Cashfrom Investing Activities
- -16.78
- Cashfrom Financing Activities
- 9.09
- Net Changein Cash
- -1.97
- Period
- 2022-12-31
- Total Revenue
- 35.36
- Selling/ General/ Admin Expenses Total
- 5.83
- Depreciation/ Amortization
- 0.61
- Other Operating Expenses Total
- 8.12
- Total Operating Expense
- 34.08
- Operating Income
- 1.28
- Net Income Before Taxes
- 3.45
- Net Income
- 3.01
- Diluted Normalized EPS
- 0.4
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Ambalal Sarabhai Enterprises Technical
Moving Average
SMA
- 5 Day39.3
- 10 Day38.8
- 20 Day37.74
- 50 Day40.14
- 100 Day47.65
- 300 Day54.29
Ambalal Sarabhai Enterprises Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Ind-swift Laboratories
- 75.94
- -4.6
- -5.71
- 186
- 74
- 450.67
- Brooks Laboratories
- 139
- -1
- -0.71
- 202.8
- 72.51
- 409.45
- Ambalal Sarabhai Enterprises
- 37.51
- -0.44
- -1.16
- 77.7
- 34.11
- 287.45
- Pharmaids Pharmaceuticals
- 65
- 0
- 0
- 87.46
- 31.9
- 226.11
- Bharat Immunologica And Bio Corp
- 23.13
- -0.29
- -1.24
- 35.88
- 19
- 99.88
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Ind-swift Laboratories
- 3.42
- 0.51
- 13.45
- 8.52
- Brooks Laboratories
- -
- 5.6
- -21.61
- -27.47
- Ambalal Sarabhai Enterprises
- 51.32
- 2.12
- 23.77
- 12.86
- Pharmaids Pharmaceuticals
- -
- 3.18
- -17.27
- -69.29
- Bharat Immunologica And Bio Corp
- -
- 1.15
- -23.67
- -16.7
Ambalal Sarabhai Enterprises Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-Feb-25
- Quarterly Results
- 12-Nov-24
- Quarterly Results
- 09-Aug-24
- Quarterly Results
- 24-May-24
- Audited Results
- 13-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 19-Aug-23
- A.G.M.
- 10-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results
- 10-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 29-Jun-24
- 06-Jun-24
- AGM
- 29-Mar-24
- 21-Feb-24
- POM
- 08-Dec-23
- 02-Nov-23
- POM
- 28-Sept-23
- 25-Aug-23
- AGM
- 23-Sept-21
- 11-Aug-21
- AGM
